Annovis Bio Launches 36-Month Open-Label Extension Study for Parkinson's Disease

Event summary

  • Annov/vis Bio will begin enrollment for an Open-Label Extension (OLE) study in January 2026.
  • The study aims to enroll 500 patients and will evaluate the long-term safety and efficacy of buntanetap in Parkinson's disease patients.
  • The study includes two cohorts: former clinical trial participants and patients receiving deep brain stimulation (DBS) treatment.
  • The study is designed to help Annovis meet FDA-mandated patient exposure requirements for a future New Drug Application (NDA) submission.

The big picture

This study represents a critical regulatory milestone for Annovis Bio, as the company aims to satisfy the FDA's specific requirements for long-term patient exposure and dosing data. By targeting underserved populations like DBS patients, the company is also attempting to expand the clinical utility and market potential of its lead candidate, buntanetap, in the complex landscape of neurodegenerative disease treatments.

What we're watching

NDA Readiness
The ability of the study to successfully reach the required patient exposure thresholds for an FDA submission.
DBS Interaction
Whether the inclusion of the DBS cohort can demonstrate a meaningful additive benefit for buntanetap.
E_longitudinal_data
The accumulation of long-term safety and biomarker data over the 36-month period to support disease-modifying claims.

Related topics

Biotechnology